You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients

Sanofi and Regeneron’s PD-1 inhibitor Libtayo has demonstrated positive overall survival (OS) results in a Phase III trial in advanced cervical cancer.